Bioanalytics – Chemical
2019 PharmSci 360
Drug-intercalated nanoparticles are one pharmaceutical delivery modality being developed to target the release of small-molecule treatments to tumor tissues while minimizing the concentrations of free drug in the plasma. Characterizing the in vivo pharmacokinetics of these nanoparticles requires measurement of the released drug that is circulating in the plasma and the drug that remains bound within the particle. The development of bioanalytical assays is quite challenging as the drug plasma concentrations, by design, are very low while the concentrations of nanoparticles are orders of magnitude greater. Any disruption of the nanoparticles during sample processing will release the bound drug and completely mask the free drug concentrations. Therefore, assays must be able to quantitatively remove the intact nanoparticles from the free drug to accurately measure free drug concentrations.